Viral Mediated Type I Interferon Induction
Viral Mediated Type I Interferon Induction
批准号:
8636981
负责人:
GENHONG CHENG
金额:
$37.84万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2016-03-31
关键词:
Antiviral ResponseBindingBoxingCancer CenterCellsCollaborationsComplexDNADNA Polymerase IIIDNA Virus InfectionsDNA VirusesDataDeubiquitinating EnzymeDeubiquitinationDiseaseDisease modelEvolutionFamily memberFeedbackFutureGenesGenetic TranscriptionGoalsHerpesvirus 1Host DefenseIFNAR1 geneIRF3 geneImmune responseImmunologic ReceptorsInfectionInterferon ActivationInterferon Type IInterferonsLaboratoriesLeadLinkMediatingNF-kappa BNucleic AcidsPathway interactionsPattern recognition receptorPhosphorylationPhosphotransferasesPlayProductionProtein FamilyRNARNA SequencesRNA VirusesReceptor ActivationReceptor SignalingRecruitment ActivityRegulationResearchResearch ProposalsRoleSignal PathwaySignal TransductionSignal Transduction PathwaySignaling MoleculeSpecificityTBK1 geneTLR3 geneTLR4 geneTNF receptor-associated factor 3Therapeutic AgentsToll-like receptorsTransfectionUbiquitinationViralVirusVirus Diseasesbasebiodefensecombatcytokinegenital herpeshelicaseinduced pluripotent stem cellnovelnovel therapeuticspathogenpublic health relevancereceptorresearch studyresponsesensortype I interferon receptorubiquitin ligaseviral DNAviral RNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by The long term goal of this research proposal is to determine the mechanisms by which different signal transduction pathways lead to Interferon (IFN) induction in response to infections with DNA and RNA viruses. To combat viral infections most nucleated vertebrate cells are able to produce cytokines known as type I IFNs, which signal through the type I IFN receptor (IFNAR1), leading to activation of the JAK/STAT pathway and subsequent induction of a large set of genes important in antiviral responses. On the other hand, as a result of co-evolution, many viruses have developed strategies to inhibit the ability of host cells to either produce or respond to IFN. To understand how this network of host/pathogen interactions leads to disease, we need to define specific IFN induction pathways. Together with other groups, we have previously demonstrated that Toll-Like Receptors (TLRs) can mediate IFN production and antiviral responses through activation of IFN regulatory factors IRF3 and IRF7. Recent studies have also uncovered RIG-I like receptor (RLR) family members as intracellular nucleic acid sensors that can detect viral RNA sequences; however, the receptors responsible for recognizing intracellular viral DNA still remain to be determined. Research in our laboratory has been focused on identifying the intermediate signaling components and pathways that link different pattern recognition receptors, like TLRs and RLRs, to the common IRF3/7-dependent IFN induction in host innate immune responses against viral infections. Surprisingly, we have found that while TNF receptor associated factor 3 (TRAF3) deficient cells are defective in IFN induction in response to RNA viral infections, they produce elevated levels of IFN in response to DNA viral infections. The goal of this application is to gain a functional and mechanistic understanding of critical signaling molecules such as TRAF3 in host biodefense against DNA and RNA viral infections. We propose experiments to understand how TRAF3 has opposite functions in regulating RNA versus DNA induced type I interferon inductions. We will determine the mechanism responsible for and potential application of enhancing interferon production against DNA viral infection by activation of the non-canonical NF-kB activation pathway. We will also define the role and specificity of a new RIG-I like DEAD box containing DNA sensor and dissect its mediated type I interferon induction pathway in host response to DNA viruses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10222540
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10174522
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10461773
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
-
批准号:10388193
-
项目类别:
-
资助金额:$75.0万
-
财政年份:2018
-
负责人:GENHONG CHENG
-
依托单位:
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
-
批准号:9925059
-
项目类别:
-
资助金额:$75.04万
-
财政年份:2018
-
负责人:GENHONG CHENG
-
依托单位:
IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
-
批准号:8039043
-
项目类别:
-
资助金额:$22.54万
-
财政年份:2011
-
负责人:GENHONG CHENG
-
依托单位:
IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
-
批准号:8208992
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2011
-
负责人:GENHONG CHENG
-
依托单位:
Mitiagrion of Radiation Damage by Mechanisms of Innate Immune Regulation
-
批准号:8011751
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2010
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7741382
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8091282
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8481502
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8282723
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7868050
-
项目类别:
-
资助金额:$37.12万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7687186
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7644341
-
项目类别:
-
资助金额:$28.28万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7388575
-
项目类别:
-
资助金额:$28.28万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:8067083
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7810716
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Viral Mediated Type I Interferon Induction
-
批准号:7587981
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2006
-
负责人:GENHONG CHENG
-
依托单位:
Viral Mediated Type I Interferon Induction
-
批准号:9458084
-
项目类别:
-
资助金额:$68.78万
-
财政年份:2006
-
负责人:GENHONG CHENG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: